Shares of Abbott Laboratories (NYSE:ABT) may be up 10.7% since the start of 2013, but this stock has lagged behind the S&P 500 index and many of its health care peers, including Boston Scientific (NYSE:BSX) and Johnson & Johnson. Abbott's next big catalyst will be its second-quarter results, which are set to be revealed tomorrow morning, but will earnings wow investors, or will they miss estimates and disappoint?
In the following video, health care analyst Max Macaluso explains the three main sections in tomorrow's report that investors should watch. Special attention should be paid to medical device sales, which weighed heavily on Abbott and other companies in this sector last quarter.
Max Macaluso, Ph.D. has no position in any stocks mentioned. The Motley Fool recommends Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.